Back to News
Market Impact: 0.3
Clene Inc. Reports Third Quarter 2026 Financial Results and Recent Operating Highlights
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCorporate Earnings
Clene Inc. said it submitted a New Drug Application to the FDA in October 2026 seeking accelerated approval for CNM-Au8 to treat amyotrophic lateral sclerosis. The company also announced third-quarter 2026 financial results, but the provided text contains no financial figures or further operating details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
CLNN0.35
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- After the midterms, a bigger clash over data centers could be coming
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform